Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin

Abstract Purpose: Recent sequencing studies revealed that a subset of colorectal cancer harbors a significantly higher number of somatic mutations.  These hypermutated tumors show distinct clinicopathologic features.  However, the prognostic impact of the hypermutated tumors is not clearly established. Experimental design: We analyzed tumor mutation burden (TMB) fr|om targeted next-generation sequencing data of 40 major genes in 516 patients with colorectal cancer.  TMB was defined as total number of nonsynonymous mutations per tumor.